BusinessMelinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient PopulationsBy Nasdaq OMXApr 23, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018By Nasdaq OMXApr 23, 2018, 11:30 AM UTC
